Sorafenib US FDA Label

  • Compound: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
  • Description: Sorafenib is a member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group. It has a role as an antineoplastic agent, an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor, a tyrosine kinase inhibitor, an angiogenesis inhibitor, an anticoronaviral agent and a ferroptosis inducer. It is a pyridinecarboxamide, a member of monochlorobenzenes, an aromatic ether, a member of (trifluoromethyl)benzenes and a member of phenylureas.

Identifiers (4)

  • International Nonproprietary Name: Sorafenib [INN] (Source: PubChem)
  • KEGG Drug ID: D08524 (Source: PubChem)
  • USFDA Precision ID: UNII-9ZOQ3TZI87 (Source: PubChem)
  • US Adopted Name: SORAFENIB [USAN] (Source: PubChem)